Key facts
- This page summarizes Wright Michael G.'s Form 3 filing for Conexeu Sciences Inc. (CNXU).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 27 May 2026, 14:05.
Wright Michael G. - 11 May 2026 Form 3 Insider Report for Conexeu Sciences Inc. (CNXU)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CNXU
- Reported as of
- 11 May 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 27 May 2026, 14:05:48 UTC
- Next SEC filing
- 28 May 2026
- Source filing
- View source filing
- Reporting owner signature
- Wright Michael G.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Wright Michael G. filed Form 3 for Conexeu Sciences Inc. (CNXU) on 27 May 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002137182
Primary reporting owner
Wright Michael G.
- Relationship
- 10%+ Owner
- Address
- 18 VICTOR, MILLE ISLES
- Signature
- Wright Michael G.
- Signature date
- 27 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNXU
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 750,000
- Date
- 11 May 2026
- Ownership
- Direct
CNXU
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,498,048
- Date
- 11 May 2026
- Ownership
- N3GU Investments LLC
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNXU
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.4000
- Footnotes
- F2
CNXU
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 May 2026
- Ownership
- N3GU Investments LLC
- Underlying class
- Common Stock
- Underlying amount
- 78,595
- Exercise price
- $0.8000
- Footnotes
- F1, F3
CNXU
holding
Derivative
Performance Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 May 2026
- Ownership
- N3GU Investments LLC
- Underlying class
- Common Stock
- Underlying amount
- 900,000
- Exercise price
- $0.001000
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.
Footnote F2
The Stock Options were granted on June 9, 2025 and vested immediately upon the grant date.
Footnote F3
The Warrants were granted on January 21, 2025 and vested immediately upon the grant date.
Footnote F4
The Performance Warrants were granted on June 5, 2025. 150,000 Performance Warrants have vested. The remainder of the Performance Warrants will vest and be exercisable upon the following milestone events: (i) 250,000 Performance Warrants upon the Issuer's listing its shares of common stock on a recognized stock exchange in North America; (ii) 250,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of >$80,000,000 in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (iii) 250,000 Performance Warrants upon the Issuer's submitting a 510(k) application to the United States Food and Drug Administration.